会员体验
专利管家(专利管理)
工作空间(专利管理)
风险监控(情报监控)
数据分析(专利分析)
侵权分析(诉讼无效)
联系我们
交流群
官方交流:
QQ群: 891211   
微信请扫码    >>>
现在联系顾问~
热词
    • 1. 发明申请
    • ELECTROCHEMICAL ACTUATORS
    • 电化学执行器
    • US20120175998A1
    • 2012-07-12
    • US13328504
    • 2011-12-16
    • Yet-Ming ChiangTimothy E. ChinMichael J. CimaJ. Richard Gyory
    • Yet-Ming ChiangTimothy E. ChinMichael J. CimaJ. Richard Gyory
    • H02N11/00
    • H01M14/00F03G7/005H01M4/131H01M4/134H01M10/052H01M10/058
    • Devices and methods for providing electrochemical actuation are described herein. In one embodiment, an actuator device includes an electrochemical cell including a negative electrode and a positive electrode At least a portion of the negative electrode is formed with a material formulated to at least one of intercalate, de-intercalate, alloy with, oxidize, reduce, or plate with a first portion of the positive electrode to an extent different than with a second portion of the positive electrode such that a differential strain is imparted between the first portion and the second portion of the positive electrode and such that at least a portion of the electrochemical cell is displaced. The electrochemical cell includes a portion that is pre-bent along an axis of the electrochemical cell to define a fold axis and the displacement of the at least a portion of the electrochemical cell is maximized along the fold axis.
    • 本文描述了用于提供电化学致动的装置和方法。 在一个实施例中,致动器装置包括包括负极和正极的电化学电池。负极的至少一部分由配制成插层,去插入,合金,氧化,还原的至少一种的材料形成 或者具有与正极的第二部分不同的程度的正极的第一部分的板,使得在正极的第一部分和第二部分之间施加微分应变,使得至少一部分 的电化学电池被移位。 电化学电池包括沿着电化学电池的轴线预弯曲以限定折叠轴线的部分,并且电化学电池的至少一部分的位移沿折叠轴线最大化。
    • 2. 发明申请
    • SYSTEMS AND METHODS FOR DELIVERING A THERAPEUTIC AGENT
    • 用于递送治疗剂的系统和方法
    • US20110275997A1
    • 2011-11-10
    • US13101749
    • 2011-05-05
    • Glenn R. BoomaAlessandro PizzocheroJ. Richard Gyory
    • Glenn R. BoomaAlessandro PizzocheroJ. Richard Gyory
    • A61M37/00
    • A61M5/145A61M5/14248A61M31/00A61M35/00A61M37/00A61M2005/14506A61M2005/14513
    • Devices, methods, and kits for delivering a therapeutic agent to a patient are disclosed herein. In one embodiment, an apparatus comprises a reservoir for containing a fluid, a first actuator, a transfer structure, and a second actuator. The first actuator has a first configuration and a second configuration and is configured to exert a first force on the reservoir when moved from its first configuration to its second configuration such that a first volume of fluid within the reservoir is communicated out of the fluid reservoir. The transfer structure is disposed between the first actuator and the reservoir and has a surface configured to engage the reservoir such that the first force exerted by the first actuator is distributed across a surface of the reservoir engaged by the transfer structure. The second actuator has a first configuration and a second configuration and is configured to exert a second force on the reservoir when the second actuator is moved from its first configuration to its second configuration such that a second volume of fluid within the reservoir is communication out of the fluid reservoir.
    • 本文公开了用于将治疗剂递送至患者的装置,方法和试剂盒。 在一个实施例中,装置包括用于容纳流体的储存器,第一致动器,转印结构和第二致动器。 第一致动器具有第一构造和第二构造,并且构造成当从其第一构型移动到其第二构造时在储存器上施加第一力,使得储存器内的第一体积的流体被连通出流体储存器。 转移结构设置在第一致动器和储存器之间,并且具有构造成与储存器接合的表面,使得由第一致动器施加的第一力分布在由传送结构接合的储存器的表面上。 第二致动器具有第一构造和第二构造,并且构造成当第二致动器从其第一构型移动到其第二构造时在储存器上施加第二力,使得储存器内的第二体积的流体从 流体储存器。
    • 6. 发明授权
    • Device and method of iontophoretic drug delivery
    • 离子电渗药物递送的装置和方法
    • US5993435A
    • 1999-11-30
    • US139036
    • 1998-08-24
    • Ronald P. HaakJ. Richard GyoryFelix Theeuwes
    • Ronald P. HaakJ. Richard GyoryFelix Theeuwes
    • A61N1/30
    • A61N1/0444A61N1/0448A61N1/0436
    • A selectively permeable membrane (14) is positioned between the agent reservoir (15) and the electrode (11) of a donor electrode assembly (8) in an iontophoretic delivery device (10). Optionally, an electrolyte reservoir (13) is positioned intermediate the electrode (11) and the agent reservoir (15). In certain embodiments, the membrane (14) is permeable to species of less than a predetermined molecular weight and substantially less permeable to species of greater than the predetermined molecular weight. The agent is capable of dissociating into agent ions and counter ions. The size selectivity of the membrane (14), the molecular weight of the agent ions, the molecular weight of the counter ions, and optionally the molecular weight of the electrolyte ions are selected to (A) inhibit agent ions from interacting with the electrode (11), and from permeating into the electrolyte reservoir (13), where they might otherwise be degraded and (B) inhibit electrolyte ions, having a charge similar to that of the agent ions, from permeating into the agent reservoir (15) and competing with the agent ions for iontophoretic delivery into the patient.
    • 选择性渗透膜(14)位于药剂储存器(15)和离子电渗输送装置(10)中的施主电极组件(8)的电极(11)之间。 可选地,电解质储存器(13)位于电极(11)和药剂储存器(15)之间。 在某些实施方案中,膜(14)对于小于预定分子量的物质是可渗透的,并且对于大于预定分子量的物质基本上较不可渗透。 该试剂能够解离成试剂离子和抗衡离子。 选择膜(14)的尺寸选择性,试剂离子的分子量,抗衡离子的分子量和任选的电解质离子的分子量以使(A)抑制剂离子与电极相互作用( 11),并且从渗透到电解质储存器(13)中,否则可能会降解,并且(B)抑制具有类似于试剂离子的电荷的电解质离子渗透到试剂储存器(15)中并且竞争 用离子电渗疗法输送到患者体内。
    • 9. 发明授权
    • Device and method of iontophoretic drug delivery
    • 离子电渗药物递送的装置和方法
    • US5496266A
    • 1996-03-05
    • US941421
    • 1992-10-27
    • Ronald P. HaakJ. Richard GyoryFelix Theeuwes
    • Ronald P. HaakJ. Richard GyoryFelix Theeuwes
    • A61N1/30
    • A61N1/0444A61N1/0448A61N1/0436
    • A selectively permeable membrane (14) is positioned between the agent reservoir (15) and the electrode (11) of a donor electrode assembly (8) in an iontophoretic delivery device (10). Optionally, an electrolyte reservoir (13) is positioned intermediate the electrode (11) and the agent reservoir (15). In certain embodiments, the membrane (14) is permeable to species of less than a predetermined molecular weight and substantially less permeable to species of greater than the predetermined molecular weight. The agent is capable of dissociating into agent ions and counter ions. The size selectivity of the membrane (14), the molecular weight of the agent ions, the molecular weight of the counter ions, and optionally the molecular weight of the electrolyte ions are selected to (A) inhibit agent ions from interacting with the electrode (11), and from permeating into the electrolyte reservoir (13), where they might otherwise be degraded and (B) inhibit electrolyte ions, having a charge similar to that of the agent ions, from permeating into the agent reservoir (15) and competing with the agent ions for iontophoretic delivery into the patient.
    • PCT No.PCT / US90 / 02414 Sec。 371日期:1992年10月27日 102(e)1992年10月27日的PCT日期1990年4月30日PCT。选择性渗透膜(14)位于药剂储存器(15)和施主电极组件(8)的电极(11)之间, 离子电渗输送装置(10)。 可选地,电解质储存器(13)位于电极(11)和药剂储存器(15)之间。 在某些实施方案中,膜(14)对于小于预定分子量的物质是可渗透的,并且对于大于预定分子量的物质基本上较不可渗透。 该试剂能够解离成试剂离子和抗衡离子。 选择膜(14)的尺寸选择性,试剂离子的分子量,抗衡离子的分子量和任选的电解质离子的分子量以使(A)抑制剂离子与电极相互作用( 11),并且从渗透到电解质储存器(13)中,否则可能会降解,并且(B)抑制具有类似于试剂离子的电荷的电解质离子渗透到试剂储存器(15)中并且竞争 用离子电渗疗法输送到患者体内。